FGFR3 and urothelial carcinoma: A phase II study FIGHT-201 (NCT02872714) was conducted to evaluate pemigatinib in patients (n = 64) with metastatic or surgically-unresectable urothelial carcinoma with FGFR3 mutations or fusions progressed after systemic treatment.